SEC Tracker
Get the app

Humanigen

Humanigen Q1 FY22: revenue $1.0M, up 113%; diluted EPS −$0.32

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract

Key figures from this report

These are the numbers Humanigen reported for Q1 FY22, the quarter ended Mar 31, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.0M+113% from $486K in Q1 FY2110-Q income statement, on EDGAR
  2. Net income−$21.3MAgainst −$65.6M in Q1 FY2110-Q income statement, on EDGAR
  3. Diluted EPS−$0.32No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$68.9M−26% from $92.9M in Q1 FY2110-Q balance sheet, on EDGAR
  5. Cash from operations−$19.4MAgainst −$35.8M in Q1 FY2110-Q cash flow statement, on EDGAR

View on EDGAR

Open in the app

Get an email when Humanigen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX

Data on this page was fetched . The filing on SEC.gov is the record.